ArticleParasites & vectors2026
Endothelial proteomic response to Dirofilaria repens somatic antigens and the Dr20/22 protein reveals parasite-driven modulation of angiogenesis.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough Dirofilaria repens induces perivascular proliferation in subcutaneous nodules, the molecular factors driving this angiogenic response remain unknown. The objective of this study is to investigate the activation of the angiogenic mechanism in an in vitro model of human vascular endothelial cells (HUVECs) stimulated with D. repens somatic antigen (DrSA) and Dr20/22 protein, identifying the key pathways underlying the vascular pathology caused by the parasite.
methodsAfter 24 h of stimulation with vascular endothelial growth factor A (VEGF-A), DrSA, Dr20/22, DrSA+VEGF-A, and Dr20/22+VEGF-A, cell viability was assessed, and proteins from the cell lysate and supernatant of HUVEC cultures were processed. Proteomic profiles were analysed by data-independent acquisition/label-free quantitation/liquid chromatography-tandem mass spectrometry (DIA-LFQ LC-MS/MS), and bioinformatics analyses (Gene Ontology, enrichment pathway analysis) were performed to identify proteins differentially expressed in relation to the angiogenic process in subcutaneous dirofilariasis.
resultsSupernatant analysis showed that DrSA+VEGF-A and Dr20/22+VEGF-A induced the most robust pro-angiogenic response compared to single treatments. Co-stimulation significantly upregulated key secreted proteins, including angiopoietin-2 (ANGPT2), cadherin-5 (CDH5), and multimerin-1 (MMRN1). This synergistic secretome, characterized by enriched angiogenesis pathways, identifies secreted endothelial cell-specific molecule 1 (ESM1) and matrix metalloproteinase-2 (MMP2) as primary drivers of vascular activation and remodelling in the host-parasite interface.
conclusionsDrSA and Dr20/22 act as key molecular drivers that manipulate host angiogenesis. While their synergy with VEGF-A clarifies the origin of vascular changes in subcutaneous dirofilariasis, further research is essential to fully characterize the specific pathways governing vascular pathology and subcutaneous nodule formation. These investigations will deepen the scientific understanding of host-parasite interactions and the disease's clinical etiopathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.